Evaxion Reshapes Executive Team to Drive AI-Immunology Platform Growth and Strategic Partnerships

Evaxion Updates Executive Leadership to Accelerate AI-Immunology™ Platform Value

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company specializing in AI-driven vaccine development, has announced key changes in its executive management. Christian Kanstrup has stepped down as CEO. Dr. Birgitte Rønø, currently Chief Scientific Officer, will serve as interim CEO during the search for a permanent replacement. Additionally, Thomas Schmidt has been appointed permanent Chief Financial Officer, after serving in an interim capacity since November 2024.

These leadership changes are aligned with Evaxion’s strategy to enhance value from its proprietary AI-Immunology™ platform and its pipeline, built over 17 years. The Board seeks a permanent CEO with a strong focus on business development, proven transformational leadership, and the ability to drive strategic partnerships. Dr. Rønø, part of Evaxion’s executive team since 2021 and with the company since 2017, will maintain leadership stability throughout the transition.

Strategic Implications of the Leadership Transition

Christian Kanstrup’s departure signals a strategic shift at Evaxion. By appointing Dr. Rønø as interim CEO, the company ensures continuity without disrupting its operations. Her long tenure and scientific leadership provide a steady hand during this period.

The Board’s criteria for the new CEO highlight a pivot from research and development to commercialization and partnership growth. After nearly two decades of platform development, Evaxion is positioning itself to capitalize on strategic collaborations and potential transactions that unlock the value of its AI-Immunology™ technology.

Confirming Thomas Schmidt as permanent CFO strengthens the company’s financial leadership amid this change. His prior interim experience since late 2024 makes him well-placed to support Evaxion’s next phase.

Overall, the management adjustments suggest a clear, business-driven approach to advancing the company’s proprietary platform and portfolio, aiming for impactful partnerships and commercial outcomes.

About Evaxion

Evaxion is a TechBio company leveraging its AI-based platform, AI-Immunology™, to innovate in vaccine and immunotherapy development. Its AI models analyze the human immune system to design novel treatments for cancer, bacterial infections, and viral diseases.

The company has advanced a clinical-stage oncology pipeline focused on personalized vaccines, alongside a preclinical pipeline targeting infectious diseases with significant unmet needs. Evaxion’s commitment is to deliver targeted therapies that improve patient outcomes.